Edwards LifesciencesNYSE: EW

Vancouver, British Columbia--(Newsfile Corp. - June 19, 2024) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") announces that the Board of directors has determined that its in the best interest of the Company to return capital to its shareholders by way of a reduction in stated capital of the Company. The Company will call a special meeting of its shareholders, to be held in August 2024 (the "Meeting"), where shareholders will be asked to consider and, if advisable, approve, among other things, a reduction in the stated capital of the Company (the "Capital Reduction"), which is currently $39,868,761, by up to $ 3 million, pursuant to the Business Corporations Act (British Columbia), for the purposes of distributing to the holders of common shares of the Company a portion of the Company's cash in the amount of $0.03 per common share (the "Distribution").

IRVINE, CA--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company) (NYSE: BDX), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care. Edwards will use the after-tax cash proceeds to fund strategic growth investments. The sale enhances Edwards' balance sheet flexibilit.

Investors are optimistic about Edward Lifesciences (EW), led by the strong performance of its SAPIEN 3 Ultra RESILIA platform and strong solvency.

This is how Edwards Lifesciences (EW) and SNDL Inc. (SNDL) have fared in comparison to their sector in the current year.

Investors seeking stocks poised to surpass quarterly earnings expectations should consider utilizing the Zacks Earnings ESP.

Examine the shift in Edwards Lifesciences' revenue from global markets and how it is influencing Wall Street's forecasts and the potential of the company's stock.

The impressive performance of the SAPIEN 3 Ultra RESILIA platform and the continued growth of TAVR contributed to Edwards Lifesciences (EW) seeing strong revenue in the first quarter.

While the revenue and EPS figures for Edwards Lifesciences (EW) offer insight into its quarterly performance ending in March 2024, it could be beneficial to also evaluate how certain important metrics stack up against analyst expectations and the previous year's figures.

Edwards Lifesciences (EW) reported earnings of $0.66 per share for the quarter, surpassing the Zacks Consensus Estimate of $0.64 per share. This is an increase from earnings of $0.62 per share in the same quarter last year.